Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells

Masuyama,Hisashi; Nakamura,Keiichiro; Nobumoto,Etsuko; Hiramatsu,Yuji

doi:10.3892/ijo.2016.3611

Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells

Authors:
- Hisashi Masuyama
- Keiichiro Nakamura
- Etsuko Nobumoto
- Yuji Hiramatsu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentist and Pharmaceutical Science, Okayama, Japan
Published online on: July 6, 2016 https://doi.org/10.3892/ijo.2016.3611
Pages: 1211-1220

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelial ovarian cancer remains the most devastating gynecologic cancer with drug resistance and rapid recurrence. Pregnane X receptor (PXR) is a nuclear receptor that affects drug metabolism/efflux and drug-drug interaction through control of multiple drug resistance 1 (MDR1), which implies a major role in multidrug resistance, and other genes. We examined whether the inhibition of PXR-mediated pathway using siRNA interference and an antagonist for PXR could influence the paclitaxel and cisplatin cytotoxicity in ovarian cancer cells. PXR agonists, phthalate and pregnenolone had significant positive effects on cytochrome P450 (CYP) 3A4 expression and PXR-mediated transcription through the CYP3A4 promoter, whereas MDR1 expression and PXR-mediated transcription though the MDR1 promoter were significantly increased in the presence of paclitaxel or cisplatin. Downregulation of PXR suppressed the augmented MDR1 expression and PXR-mediated transcription by PXR ligands, and significantly enhanced cell growth inhibition and apoptosis in the presence of paclitaxel or cisplatin. Additionally, ketoconazole, a PXR antagonist, suppressed the augmented MDR1 expression and PXR-mediated transactivation by paclitaxel and cisplatin, and enhanced cell growth inhibition and apoptosis in their presence. In conclusion, inhibition of PXR-mediated pathways could be a novel means of augmenting sensitivity, or overcoming resistance to anticancer agents for ovarian cancer.

View Figures

View References

1	Rubin SC, Randall TC, Armstrong KA, Chi DS and Hoskins WJ: Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol. 93:21–24. 1999.PubMed/NCBI
2	Armstrong DK: Relapsed ovarian cancer: Challenges and management strategies for a chronic disease. Oncologist. 7(Suppl 5): 20–28. 2002. View Article : Google Scholar : PubMed/NCBI
3	National Institute for Health and Care Excellence. Guidance on the use of paclitaxel in the treatment of ovarian cancer. http://www.nice.org.uk/guidance/ta55. Accessed January 22, 2003
4	McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
5	Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst. 92:699–708. 2000. View Article : Google Scholar : PubMed/NCBI
6	Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H and Haga N: Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal. Cancer Sci. 94:15–21. 2003. View Article : Google Scholar : PubMed/NCBI
7	Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE and Gottesman MM: P-glycoprotein: From genomics to mechanism. Oncogene. 22:7468–7485. 2003. View Article : Google Scholar : PubMed/NCBI
8	Ling V: Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol. 40(Suppl): S3–S8. 1997. View Article : Google Scholar : PubMed/NCBI
9	Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR and Bonnet JD: A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer. 75:815–820. 1995. View Article : Google Scholar : PubMed/NCBI
10	Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, Lokhorst H, van der Lelie J, Dohner H, Gerhartz H, et al; European Organization for Research and Treatment of Cancer (EORTC); Leukaemia Cooperative Group (LCG); Dutch Haemato-Oncology Cooperative Study Group (HOVON). Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: An EORTC-HOVON randomized phase III study (06914). Br J Haematol. 115:895–902. 2001. View Article : Google Scholar
11	Leonard GD, Fojo T and Bates SE: The role of ABC transporters in clinical practice. Oncologist. 8:411–424. 2003. View Article : Google Scholar : PubMed/NCBI
12	Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterström RH, et al: An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell. 92:73–82. 1998. View Article : Google Scholar : PubMed/NCBI
13	Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT and Kliewer SA: The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 102:1016–1023. 1998. View Article : Google Scholar : PubMed/NCBI
14	Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Bäckman M, Ohlsson R, Postlind H, Blomquist P and Berkenstam A: Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA. 95:12208–12213. 1998. View Article : Google Scholar : PubMed/NCBI
15	Zhang H, LeCulyse E, Liu L, Hu M, Matoney L, Zhu W and Yan B: Rat pregnane X receptor: Molecular cloning, tissue distribution, and xenobiotic regulation. Arch Biochem Biophys. 368:14–22. 1999. View Article : Google Scholar : PubMed/NCBI
16	Blumberg B, Sabbagh W Jr, Juguilon H, Bolado J Jr, van Meter CM, Ong ES and Evans RM: SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 12:3195–3205. 1998. View Article : Google Scholar : PubMed/NCBI
17	Pascussi JM, Jounaidi Y, Drocourt L, Domergue J, Balabaud C, Maurel P and Vilarem MJ: Evidence for the presence of a functional pregnane X receptor response element in the CYP3A7 promoter gene. Biochem Biophys Res Commun. 260:377–381. 1999. View Article : Google Scholar : PubMed/NCBI
18	Schuetz EG, Brimer C and Schuetz JD: Environmental xenobiotics and the antihormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP3A23 hormone response element. Mol Pharmacol. 54:1113–1117. 1998.PubMed/NCBI
19	de Wildt SN, Kearns GL, Leeder JS and van den Anker JN: Cytochrome P450 3A: Ontogeny and drug disposition. Clin Pharmacokinet. 37:485–505. 1999. View Article : Google Scholar
20	Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS and Callahan AM: The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol. 15:387–398. 1995. View Article : Google Scholar : PubMed/NCBI
21	Synold TW, Dussault I and Forman BM: The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 7:584–590. 2001. View Article : Google Scholar : PubMed/NCBI
22	Geick A, Eichelbaum M and Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 276:14581–14587. 2001. View Article : Google Scholar : PubMed/NCBI
23	Kliewer SA, Goodwin B and Willson TM: The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism. Endocr Rev. 23:687–702. 2002. View Article : Google Scholar : PubMed/NCBI
24	Hartley DP, Dai X, Yabut J, Chu X, Cheng O, Zhang T, He YD, Roberts C, Ulrich R, Evers R, et al: Identification of potential pharmacological and toxicological targets differentiating structural analogs by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell lines. Pharmacogenet Genomics. 16:579–599. 2006. View Article : Google Scholar : PubMed/NCBI
25	Guzelian J, Barwick JL, Hunter L, Phang TL, Quattrochi LC and Guzelian PS: Identification of genes controlled by the pregnane X receptor by microarray analysis of mRNAs from pregnenolone 16alpha-carbonitrile-treated rats. Toxicol Sci. 94:379–387. 2006. View Article : Google Scholar : PubMed/NCBI
26	Masuyama H, Nakatsukasa H, Takamoto N and Hiramatsu Y: Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells. Mol Pharmacol. 72:1045–1053. 2007. View Article : Google Scholar : PubMed/NCBI
27	Gupta D, Venkatesh M, Wang H, Kim S, Sinz M, Goldberg GL, Whitney K, Longley C and Mani S: Expanding the roles for pregnane X receptor in cancer: Proliferation and drug resistance in ovarian cancer. Clin Cancer Res. 14:5332–5340. 2008. View Article : Google Scholar : PubMed/NCBI
28	Yue X, Akahira J, Utsunomiya H, Miki Y, Takahashi N, Niikura H, Ito K, Sasano H, Okamura K and Yaegashi N: Steroid and xenobiotic receptor (SXR) as a possible prognostic marker in epithelial ovarian cancer. Pathol Int. 60:400–406. 2010. View Article : Google Scholar : PubMed/NCBI
29	Masuyama H, Suwaki N, Tateishi Y, Nakatsukasa H, Segawa T and Hiramatsu Y: The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol. 19:1170–1180. 2005. View Article : Google Scholar : PubMed/NCBI
30	Wang Y, Masuyama H, Nobumoto E, Zhang G and Hiramatsu Y: The inhibition of constitutive androstane receptor-mediated pathway enhances the effects of anticancer agents in ovarian cancer cells. Biochem Pharmacol. 90:356–366. 2014. View Article : Google Scholar : PubMed/NCBI
31	Xie W and Evans RM: Orphan nuclear receptors: The exotics of xenobiotics. J Biol Chem. 276:37739–37742. 2001. View Article : Google Scholar : PubMed/NCBI
32	Qatanani M and Moore DD: CAR, the continuously advancing receptor, in drug metabolism and disease. Curr Drug Metab. 6:329–339. 2005. View Article : Google Scholar : PubMed/NCBI
33	Petru E, Sevin BU, Perras J, Boike G, Ramos R, Nguyen H and Averette HE: Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence. Gynecol Oncol. 38:155–160. 1990. View Article : Google Scholar : PubMed/NCBI
34	Smith JA, Ngo H, Martin MC and Wolf JK: An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecol Oncol. 98:141–145. 2005. View Article : Google Scholar : PubMed/NCBI
35	Duan Z, Brakora KA and Seiden MV: Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther. 3:833–838. 2004.PubMed/NCBI
36	Masuyama H, Hiramatsu Y, Kunitomi M, Kudo T and MacDonald PN: Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate Pregnane X receptor-mediated transcription. Mol Endocrinol. 14:421–428. 2000. View Article : Google Scholar : PubMed/NCBI
37	Masuyama H, Hiramatsu Y, Mizutani Y, Inoshita H and Kudo T: The expression of pregnane X receptor and its target gene, cytochrome P450 3A1, in perinatal mouse. Mol Cell Endocrinol. 172:47–56. 2001. View Article : Google Scholar : PubMed/NCBI
38	Wang H, Huang H, Li H, Teotico DG, Sinz M, Baker SD, Staudinger J, Kalpana G, Redinbo MR and Mani S: Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin Cancer Res. 13:2488–2495. 2007. View Article : Google Scholar : PubMed/NCBI
39	Huang H, Wang H, Sinz M, Zoeckler M, Staudinger J, Redinbo MR, Teotico DG, Locker J, Kalpana GV and Mani S: Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene. 26:258–268. 2007. View Article : Google Scholar
40	Chen Y, Tang Y, Guo C, Wang J, Boral D and Nie D: Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol. 83:1112–1126. 2012. View Article : Google Scholar : PubMed/NCBI